MLV & Co. Initiates Intercept Pharmaceuticals With Hold

Analysts at MLV & Co. initiated coverage on Intercept Pharmaceuticals, Inc. ICPT with a Hold rating, according to sources. The target price for Intercept Pharmaceuticals is set to $273. Intercept Pharmaceuticals shares have dropped 32.30% over the past 52 weeks, while the S&P 500 index has surged 11.16% in the same period. Intercept Pharmaceuticals' shares fell 3.22% to $285.01 in pre-market trading.